Amgen last summer scored a major patent win to defend its blockbuster immunology med Enbrel from impending biosimilar competition. Now, Novartis is challenging that ruling in appeals court, but analysts figure Amgen still holds an edge. At an appeals hearing Wednesday, judges heard arguments from Amgen and Novartis’ Sandoz unit over patents protecting big-selling Enbrel until 2029. While Sandoz’s… Read More »
We live in an incredible era of progress in human health. Advances in cell and gene therapies are beginning to yield powerful new treatments for some of the most devastating illnesses. With many of these new therapies we are no longer combating diseases over time, but potentially curing them in a single treatment. This is… Read More »
(Reuters) – Novartis AG, which this week announced positive interim trial results for its experimental gene therapy for spinal muscular atrophy, on Friday said investigation is underway into whether a second trial death could be related to the treatment. The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland January… Read More »
Johnson & Johnson’s Tremfya may have made its debut after key rivals, but it made waves Wednesday in the next-gen psoriasis field with Cosentyx-topping head-to-head data. At the 48-week mark, 84.5% of Tremfya patients in a phase 3 study achieved a score of 90 on the Psoriasis Area Severity Index (PASI), a commonly used metric for measuring… Read More »